BofA raised the firm’s price target on Mineralys Therapeutics (MLYS) to $51 from $46 and keeps a Buy rating on the shares following some corporate updates on the clinical development progress of lead drug lorundrostat for the treatment of uncontrolled hypertension that came with Q4 earnings. The firm’s view is that lorundrostat’s peak sales opportunity remains “underappreciated,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
- Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings
- MLYS Upcoming Earnings Report: What to Expect?
- Mineralys Reports Mixed Phase 2 Results for Lorundrostat
- Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA